ITI-722

Modify Date: 2024-01-02 09:29:25

ITI-722 structure	Common Name	ITI-722
	CAS Number	313368-91-1	Molecular Weight	393.497
	Density	1.3±0.0 g/cm3	Boiling Point	556.4±0.0 °C at 760 mmHg
	Molecular Formula	C₂₄H₂₈FN₃O	Melting Point	N/A
	MSDS	N/A	Flash Point	290.3±0.0 °C

Use of ITI-722

Lumateperone (ITI-007) is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia[1][2][3].

Name	Lumateperone
Synonym	More Synonyms

Description	Lumateperone (ITI-007) is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia[1][2][3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor
In Vitro	Lumateperone (2-30 μM) has anti-tumor activity and can inhibit cell proliferation in a dose-dependent manner[1]. Cell Proliferation Assay[1] Cell Line: RPMI-8226 cells Concentration: 2-30 μM Incubation Time: 48 hours Result: Inhibited cell growth with the IC50 value of 17.30 μM.
In Vivo	Lumateperone (i.p., 1-10 mg/kg) promotes NMDA and AMPA-induced currents in a dopamine D1 receptor-dependent manner and increases the release of dopamine and glutamate in rat mPFC slices[2]. Animal Model: Adult male Sprague-Dawley rats[2] Dosage: 1-10 mg/kg Administration: Intraperitoneal injection Result: Inhibited avoidance response at concentrations of 1, 3 and 10 mg/kg after 20 minutes. Promoted NMDA and AMPA-sensitive currents, also significantly increased dopamine and glutamate release at 10 mg/kg in mPFC cone cells of rat.
References	[1]. Jinyuan Zhang, et al. Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth. Mol Inform. 2022 Mar 30:e2200011. [2]. J Titulaer, et al. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. Eur Neuropsychopharmacol. 2022 Jul 22;62:22-35. [3]. Lumateperone

Density	1.3±0.0 g/cm3
Boiling Point	556.4±0.0 °C at 760 mmHg
Molecular Formula	C₂₄H₂₈FN₃O
Molecular Weight	393.497
Flash Point	290.3±0.0 °C
Exact Mass	393.221649
LogP	3.39
Vapour Pressure	0.0±0.0 mmHg at 25°C
Index of Refraction	1.646